Harvard Bioscience (HBIO) Reaches New 1-Year High and Low at $6.00

Harvard Bioscience, Inc. (NASDAQ:HBIO)’s share price reached a new 52-week high and low during trading on Monday . The company traded as low as $6.00 and last traded at $5.85, with a volume of 244105 shares traded. The stock had previously closed at $5.60.

HBIO has been the subject of a number of analyst reports. Zacks Investment Research raised Harvard Bioscience from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a report on Thursday, March 8th. Janney Montgomery Scott raised their price target on Harvard Bioscience from $5.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, January 24th. Benchmark raised their price target on Harvard Bioscience from $6.00 to $10.00 and gave the stock a “buy” rating in a report on Tuesday, January 23rd. Finally, ValuEngine raised Harvard Bioscience from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. One research analyst has rated the stock with a hold rating and three have given a buy rating to the stock. Harvard Bioscience currently has a consensus rating of “Buy” and a consensus price target of $7.75.

The company has a debt-to-equity ratio of 0.11, a current ratio of 3.39 and a quick ratio of 1.86. The firm has a market capitalization of $199.38, a P/E ratio of 119.00 and a beta of 1.27.

Harvard Bioscience (NASDAQ:HBIO) last posted its quarterly earnings results on Thursday, March 1st. The medical instruments supplier reported $0.05 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.05. Harvard Bioscience had a positive return on equity of 2.34% and a negative net margin of 0.85%. The firm had revenue of $27.46 million during the quarter, compared to analyst estimates of $26.60 million. equities analysts predict that Harvard Bioscience, Inc. will post 0.12 EPS for the current fiscal year.

In related news, Director George Uveges sold 22,250 shares of the stock in a transaction on Wednesday, March 14th. The stock was sold at an average price of $4.58, for a total value of $101,905.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Robert E. Gagnon sold 97,087 shares of the stock in a transaction on Wednesday, March 7th. The stock was sold at an average price of $4.62, for a total value of $448,541.94. The disclosure for this sale can be found here. Insiders sold 241,413 shares of company stock valued at $1,106,256 over the last ninety days. Corporate insiders own 7.60% of the company’s stock.

Several hedge funds have recently modified their holdings of HBIO. New York State Common Retirement Fund purchased a new stake in shares of Harvard Bioscience in the third quarter worth $321,000. Segall Bryant & Hamill LLC raised its position in shares of Harvard Bioscience by 9.8% in the fourth quarter. Segall Bryant & Hamill LLC now owns 836,318 shares of the medical instruments supplier’s stock worth $2,760,000 after buying an additional 74,307 shares in the last quarter. Algert Global LLC raised its position in shares of Harvard Bioscience by 25.7% in the fourth quarter. Algert Global LLC now owns 187,422 shares of the medical instruments supplier’s stock worth $618,000 after buying an additional 38,328 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of Harvard Bioscience by 2,013.7% in the fourth quarter. Wells Fargo & Company MN now owns 32,446 shares of the medical instruments supplier’s stock worth $107,000 after buying an additional 30,911 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Harvard Bioscience by 1.8% in the third quarter. Dimensional Fund Advisors LP now owns 1,740,790 shares of the medical instruments supplier’s stock worth $6,528,000 after buying an additional 30,068 shares in the last quarter. Institutional investors own 62.25% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Harvard Bioscience (HBIO) Reaches New 1-Year High and Low at $6.00” was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2018/04/16/harvard-bioscience-hbio-reaches-new-1-year-high-and-low-at-6-00.html.

About Harvard Bioscience

Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply